| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 Department of Radiology, Kyoto City Hospital, 1-2 Higashi-takada-cho, Mibu,
Nakagyo-ku, Kyoto 604-8845, Japan.
2 Department of Surgery, Kyoto City Hospital, Kyoto 604-8845, Japan.
OBJECTIVE. A study was conducted on hepatic fat content to investigate the frequency and clinical course of hepatic steatosis induced by tamoxifen.
MATERIALS AND METHODS. Sixty-seven patients with breast cancer treated with adjuvant tamoxifen were included. The patients underwent postoperative annual abdominal CT, both with and without contrast enhancement, for 5 years. We retrospectively reviewed unenhanced CT images and obtained hepatic and splenic CT attenuation values to calculate the liver—spleen ratio. Hepatic steatosis was defined as a liver—spleen ratio of less than 0:9, and its degree was classified as mild (liver—spleen ratio, 0:5-0:9), moderate (0-0:5), or severe (<0). The pattern of steatosis was classified as generalized, lobar, segmental, or focal.
RESULTS. In the study population, hepatic CT values decreased during therapy (p < 0.0001, t test) and increased after therapy (p < 0.0001, paired t test). Twenty-nine patients (43.2%) developed hepatic steatosis within the first 2 years; its degree was mild in 16, moderate in nine, and severe in four. Seventeen patients showed a generalized pattern of steatosis, and the other 12 showed a lobar pattern. Twenty-three of these patients showed an increase in the liver—spleen ratio after therapy to within the normal range, with a mean recovery time of 1.2 years after therapy ended. None progressed to steatohepatitis or cirrhosis.
CONCLUSION. Tamoxifen had a statistically significant influence on hepatic fat content and was associated with frequent development of hepatic steatosis. Radiologists should be aware of this phenomenon and the possible occurrence of hepatic dysfunction and should differentiate steatosis from metastasis in postoperative patients with breast cancer.
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  I. Larosche, P. Letteron, B. Fromenty, N. Vadrot, A. Abbey-Toby, G. Feldmann, D. Pessayre, and A. Mansouri Tamoxifen Inhibits Topoisomerases, Depletes Mitochondrial DNA, and Triggers Steatosis in Mouse Liver J. Pharmacol. Exp. Ther., May 1, 2007; 321(2): 526 - 535. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M Brookes, D MacVicar, and J Husband Metastatic carcinoma of the breast: the appearances of metastatic spread to the abdomen and pelvis as demonstrated by CT Br. J. Radiol., April 1, 2007; 80(952): 284 - 292. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. A. Gudbrandsen, T. H. Rost, and R. K. Berge Causes and prevention of tamoxifen-induced accumulation of triacylglycerol in rat liver J. Lipid Res., October 1, 2006; 47(10): 2223 - 2232. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. J. Lelliott, M. Lopez, R. K. Curtis, N. Parker, M. Laudes, G. Yeo, M. Jimenez-Linan, J. Grosse, A. K. Saha, D. Wiggins, et al. Transcript and metabolite analysis of the effects of tamoxifen in rat liver reveals inhibition of fatty acid synthesis in the presence of hepatic steatosis FASEB J, July 1, 2005; 19(9): 1108 - 1119. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Bruno, P. Maisonneuve, P. Castellana, N. Rotmensz, S. Rossi, M. Maggioni, M. Persico, A. Colombo, F. Monasterolo, D. Casadei-Giunchi, et al. Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial BMJ, April 23, 2005; 330(7497): 932. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
